Six building blocks could help pharma organizations slash filing timelines from months to weeks, potentially unlocking as much as $180 million in net present value for priority assets.Biopharmaceutical companies have set bold ambitions to reduce regulatory-submission timelines for new products. This is part of broader efforts and ambitions over the past decade to compress clinical […]
